The University of Chicago Header Logo

Rita Nanda

Concepts (321)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Triple Negative Breast Neoplasms
29
2025
176
7.800
Why?
Breast Neoplasms
69
2025
3019
5.970
Why?
Neoadjuvant Therapy
34
2025
383
3.610
Why?
Receptor, ErbB-2
31
2025
253
2.990
Why?
Antineoplastic Combined Chemotherapy Protocols
39
2025
2519
2.720
Why?
Antibodies, Monoclonal, Humanized
15
2024
962
2.250
Why?
Biomarkers, Tumor
24
2025
1547
1.800
Why?
Receptors, Estrogen
13
2025
395
1.580
Why?
Immunotherapy
8
2025
703
1.380
Why?
Programmed Cell Death 1 Receptor
4
2024
174
1.340
Why?
Immunoconjugates
4
2024
115
1.330
Why?
Paclitaxel
14
2025
484
1.270
Why?
Neoplasm Staging
22
2025
2013
1.240
Why?
Receptors, Progesterone
9
2025
176
1.230
Why?
B7-H1 Antigen
7
2024
279
1.210
Why?
Female
95
2025
46831
1.120
Why?
Trastuzumab
17
2024
77
1.080
Why?
Complementary Therapies
2
2024
55
1.080
Why?
Camptothecin
4
2024
197
1.070
Why?
Antineoplastic Agents
9
2022
2337
0.990
Why?
Antineoplastic Agents, Immunological
4
2023
205
0.980
Why?
Integrative Medicine
1
2024
10
0.920
Why?
Humans
106
2025
90539
0.870
Why?
Middle Aged
60
2025
26305
0.810
Why?
Tumor Microenvironment
6
2024
478
0.780
Why?
Adult
51
2025
26922
0.710
Why?
Aged
45
2025
19380
0.690
Why?
Neoplasm Metastasis
15
2024
1066
0.670
Why?
Genes, BRCA1
3
2011
192
0.630
Why?
Age Factors
1
2023
1871
0.610
Why?
Pharmacogenetics
5
2019
437
0.570
Why?
Precision Medicine
7
2023
413
0.560
Why?
Circulating Tumor DNA
3
2023
48
0.550
Why?
Neoplasm Recurrence, Local
8
2024
1356
0.550
Why?
Capecitabine
4
2024
93
0.540
Why?
Receptors, Androgen
3
2024
119
0.510
Why?
Poly(ADP-ribose) Polymerase Inhibitors
5
2021
76
0.510
Why?
Antibodies, Monoclonal
5
2024
1397
0.490
Why?
Treatment Outcome
20
2025
8367
0.480
Why?
Disease-Free Survival
9
2024
1170
0.470
Why?
Antimetabolites, Antineoplastic
4
2021
233
0.460
Why?
Clinical Decision-Making
5
2021
283
0.440
Why?
Quinazolines
5
2023
214
0.390
Why?
Prognosis
13
2025
3810
0.370
Why?
Receptors, Glucocorticoid
3
2025
141
0.370
Why?
Albumins
3
2025
135
0.370
Why?
Breast
7
2023
289
0.370
Why?
Genes, erbB-2
2
2009
25
0.370
Why?
Class I Phosphatidylinositol 3-Kinases
3
2023
64
0.360
Why?
Piperazines
3
2021
284
0.360
Why?
Mifepristone
2
2025
45
0.350
Why?
Aged, 80 and over
14
2024
6808
0.340
Why?
Magnetic Resonance Imaging
6
2024
3485
0.320
Why?
Mastectomy
3
2018
252
0.320
Why?
Drug Prescriptions
3
2019
142
0.310
Why?
Gene Expression Profiling
7
2025
1460
0.300
Why?
Neoplasms
5
2021
3029
0.300
Why?
Neoplastic Cells, Circulating
2
2020
70
0.290
Why?
Retrospective Studies
10
2025
9310
0.290
Why?
Antineoplastic Agents, Hormonal
2
2021
145
0.280
Why?
Healthcare Disparities
4
2025
433
0.270
Why?
Clinical Trials as Topic
3
2022
1141
0.270
Why?
Benzimidazoles
2
2017
107
0.260
Why?
Cohort Studies
6
2023
2893
0.260
Why?
Carboplatin
2
2017
311
0.250
Why?
Hormones
2
2023
139
0.250
Why?
DNA Methylation
5
2022
666
0.240
Why?
Maytansine
2
2021
11
0.240
Why?
Molecular Targeted Therapy
4
2021
281
0.240
Why?
Genes, BRCA2
1
2005
161
0.230
Why?
Phthalazines
2
2021
47
0.220
Why?
Sirolimus
3
2014
164
0.220
Why?
Mastectomy, Segmental
1
2024
101
0.220
Why?
Genetic Testing
2
2018
544
0.220
Why?
Survival Rate
4
2021
1899
0.220
Why?
Lymphocytes, Tumor-Infiltrating
1
2024
135
0.220
Why?
Yoga
1
2023
5
0.210
Why?
Meditation
1
2023
5
0.210
Why?
Pharmacogenomic Testing
3
2019
95
0.210
Why?
Single-Cell Analysis
1
2024
162
0.210
Why?
Proteomics
1
2024
241
0.200
Why?
Anthracyclines
1
2022
34
0.200
Why?
Mammary Neoplasms, Animal
1
2022
57
0.200
Why?
Recombinant Fusion Proteins
1
2024
565
0.200
Why?
United States
6
2025
7138
0.190
Why?
Cell-Free Nucleic Acids
1
2023
83
0.190
Why?
T-Lymphocytes, Regulatory
1
2024
314
0.190
Why?
Chemotherapy, Adjuvant
4
2024
477
0.190
Why?
Doxorubicin
4
2024
293
0.190
Why?
Phenylthiohydantoin
2
2019
46
0.190
Why?
Contrast Media
2
2023
1085
0.190
Why?
Electron Transport Complex I
1
2021
31
0.180
Why?
Benzamides
3
2019
236
0.180
Why?
Specimen Handling
1
2021
103
0.180
Why?
Lymph Nodes
1
2024
553
0.180
Why?
Brain Neoplasms
2
2018
781
0.180
Why?
Telemedicine
1
2023
196
0.180
Why?
Homologous Recombination
1
2020
53
0.180
Why?
Neoplasms, Hormone-Dependent
1
2020
36
0.170
Why?
Drug-Related Side Effects and Adverse Reactions
2
2020
203
0.170
Why?
Germ-Line Mutation
4
2020
349
0.170
Why?
Point-of-Care Systems
2
2019
146
0.170
Why?
Decision Support Systems, Clinical
2
2017
103
0.170
Why?
Imidazoles
2
2019
138
0.160
Why?
Health Knowledge, Attitudes, Practice
1
2024
539
0.160
Why?
Pyridines
1
2021
303
0.160
Why?
Ovarian Neoplasms
1
2005
773
0.160
Why?
Prescription Drugs
1
2019
34
0.160
Why?
Chemoradiotherapy, Adjuvant
1
2018
36
0.150
Why?
Cyclophosphamide
3
2024
303
0.150
Why?
Mutation
8
2023
4181
0.150
Why?
CTLA-4 Antigen
1
2018
140
0.150
Why?
Combined Modality Therapy
5
2023
1708
0.150
Why?
Genomics
3
2024
784
0.150
Why?
Radiosurgery
1
2021
286
0.150
Why?
Gene Expression Regulation, Neoplastic
5
2025
1286
0.150
Why?
Carcinoma, Ductal, Breast
3
2014
160
0.140
Why?
Medical Order Entry Systems
1
2017
27
0.140
Why?
BRCA1 Protein
2
2017
205
0.140
Why?
Practice Guidelines as Topic
2
2021
1054
0.140
Why?
PTEN Phosphohydrolase
1
2017
138
0.140
Why?
Neoplasm, Residual
3
2023
185
0.140
Why?
Protein Kinase Inhibitors
3
2019
589
0.130
Why?
Dasatinib
1
2016
38
0.130
Why?
L-Lactate Dehydrogenase
1
2016
71
0.130
Why?
Diphosphonates
1
2016
33
0.130
Why?
BRCA2 Protein
1
2017
161
0.130
Why?
Quinolines
1
2016
87
0.130
Why?
DNA, Neoplasm
1
2016
266
0.130
Why?
Bone Density Conservation Agents
1
2016
42
0.130
Why?
Physician's Role
1
2017
176
0.120
Why?
Physician-Patient Relations
2
2019
625
0.120
Why?
Meningeal Carcinomatosis
1
2015
7
0.120
Why?
Image Processing, Computer-Assisted
1
2021
1259
0.120
Why?
Vascular Endothelial Growth Factor A
2
2014
407
0.120
Why?
Meningeal Neoplasms
1
2015
66
0.120
Why?
Esophagitis
1
2014
43
0.120
Why?
Fluorodeoxyglucose F18
1
2015
143
0.120
Why?
Radiation-Sensitizing Agents
1
2014
97
0.110
Why?
Disease Progression
4
2023
1485
0.110
Why?
Genome, Human
1
2019
792
0.110
Why?
Nanoparticles
1
2015
165
0.110
Why?
Bone Neoplasms
1
2016
321
0.110
Why?
Oligonucleotide Array Sequence Analysis
4
2014
693
0.110
Why?
Follow-Up Studies
4
2024
3691
0.110
Why?
Bayes Theorem
3
2024
385
0.110
Why?
Radiation Injuries
1
2014
159
0.110
Why?
Proportional Hazards Models
3
2020
842
0.100
Why?
Young Adult
6
2021
6412
0.100
Why?
Immunohistochemistry
4
2024
1805
0.100
Why?
Nitriles
3
2019
156
0.100
Why?
Carcinoma in Situ
1
2012
52
0.100
Why?
Practice Patterns, Physicians'
1
2017
604
0.100
Why?
Predictive Value of Tests
4
2021
1741
0.090
Why?
ErbB Receptors
2
2011
499
0.090
Why?
Kinetics
2
2023
1550
0.090
Why?
Macrophages
1
2013
585
0.080
Why?
Prospective Studies
4
2020
4345
0.080
Why?
Promoter Regions, Genetic
3
2007
961
0.080
Why?
Guidelines as Topic
2
2021
161
0.080
Why?
Angiogenesis Inhibitors
1
2011
295
0.080
Why?
Logistic Models
2
2016
1216
0.070
Why?
Lymphatic Metastasis
2
2024
498
0.070
Why?
Fanconi Anemia Complementation Group F Protein
1
2007
6
0.070
Why?
Cell Line, Tumor
3
2024
2607
0.070
Why?
Maximum Tolerated Dose
2
2021
263
0.070
Why?
Transcriptome
2
2023
667
0.070
Why?
Ubiquitin-Protein Ligases
1
2007
174
0.070
Why?
Estrogen Receptor alpha
1
2007
148
0.070
Why?
Genes, Neoplasm
1
2006
38
0.070
Why?
Animals
3
2022
27690
0.070
Why?
Patient Selection
2
2021
682
0.070
Why?
Epigenesis, Genetic
3
2022
524
0.070
Why?
Survival Analysis
3
2018
1499
0.060
Why?
Aneuploidy
1
2005
57
0.060
Why?
Disease Management
2
2019
332
0.060
Why?
Chromosomes, Human, Pair 17
1
2005
108
0.060
Why?
Conserved Sequence
1
2006
211
0.060
Why?
Male
8
2023
42909
0.060
Why?
Probability
1
2005
355
0.060
Why?
Sensitivity and Specificity
2
2023
2019
0.060
Why?
Receptor, TIE-2
1
2024
18
0.060
Why?
Drug Resistance, Neoplasm
1
2007
609
0.050
Why?
Personal Satisfaction
1
2023
64
0.050
Why?
Biology
1
2023
52
0.050
Why?
Liquid Biopsy
1
2023
36
0.050
Why?
Carcinoma, Lobular
2
2014
81
0.050
Why?
Biopsy
2
2017
1192
0.050
Why?
Demography
1
2023
183
0.050
Why?
Models, Statistical
1
2005
575
0.050
Why?
Methylation
1
2023
272
0.050
Why?
Risk Factors
2
2018
5578
0.050
Why?
Amenorrhea
1
2021
28
0.050
Why?
Time Factors
2
2021
5364
0.050
Why?
Data Accuracy
1
2021
32
0.050
Why?
Drug Discovery
2
2015
110
0.050
Why?
United States Food and Drug Administration
1
2021
135
0.040
Why?
Bridged-Ring Compounds
1
2020
13
0.040
Why?
Ferredoxin-NADP Reductase
1
2020
15
0.040
Why?
Methylenetetrahydrofolate Reductase (NADPH2)
1
2020
27
0.040
Why?
Patient Satisfaction
1
2023
463
0.040
Why?
Oxazepines
1
2019
4
0.040
Why?
Taxoids
1
2020
124
0.040
Why?
Androgen Receptor Antagonists
1
2019
20
0.040
Why?
Longitudinal Studies
1
2023
1085
0.040
Why?
DNA Mutational Analysis
1
2021
528
0.040
Why?
Postmenopause
1
2020
102
0.040
Why?
Drug Recalls
1
2019
12
0.040
Why?
Heterocyclic Compounds, 3-Ring
1
2019
31
0.040
Why?
Neoplasm Invasiveness
2
2014
570
0.040
Why?
Receptors, Steroid
1
2019
42
0.040
Why?
Bevacizumab
1
2020
268
0.040
Why?
Everolimus
1
2018
36
0.040
Why?
High-Throughput Nucleotide Sequencing
1
2021
491
0.040
Why?
Europe
1
2019
328
0.040
Why?
Genotyping Techniques
1
2018
69
0.040
Why?
Research
1
2019
252
0.040
Why?
Societies, Medical
1
2021
591
0.040
Why?
Pandemics
1
2023
788
0.040
Why?
Poly (ADP-Ribose) Polymerase-1
1
2017
26
0.040
Why?
Proto-Oncogene Proteins c-akt
1
2019
342
0.040
Why?
Drug Labeling
1
2017
40
0.040
Why?
DNA Copy Number Variations
1
2018
180
0.040
Why?
Dose-Response Relationship, Drug
1
2021
1935
0.030
Why?
California
1
2017
151
0.030
Why?
CpG Islands
2
2007
158
0.030
Why?
Health Personnel
1
2019
215
0.030
Why?
Social Perception
1
2017
94
0.030
Why?
Drug Screening Assays, Antitumor
1
2016
83
0.030
Why?
src-Family Kinases
1
2016
75
0.030
Why?
Attitude to Health
1
2017
220
0.030
Why?
Kaplan-Meier Estimate
1
2018
854
0.030
Why?
Vertical Dimension
1
1995
1
0.030
Why?
Orthodontics, Corrective
1
1995
3
0.030
Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
1
2015
3
0.030
Why?
Malocclusion
1
1995
8
0.030
Why?
Azacitidine
2
2006
148
0.030
Why?
Genotype
1
2020
1855
0.030
Why?
Gene Frequency
1
2017
689
0.030
Why?
Communication
1
2019
462
0.030
Why?
Retreatment
1
2015
107
0.030
Why?
Cell Count
1
2015
200
0.030
Why?
Academic Medical Centers
1
2017
387
0.030
Why?
Analysis of Variance
2
2013
898
0.030
Why?
Lung Neoplasms
1
2006
2369
0.030
Why?
Alleles
1
2017
1138
0.030
Why?
Fatal Outcome
1
2014
298
0.030
Why?
Risk Assessment
1
2021
2335
0.030
Why?
Insulin-Like Growth Factor Binding Protein 3
1
2013
21
0.030
Why?
Insulin-Like Growth Factor II
1
2013
33
0.030
Why?
Receptor, IGF Type 1
1
2013
44
0.030
Why?
Positron-Emission Tomography
1
2015
340
0.030
Why?
Delivery of Health Care
1
2018
431
0.030
Why?
Dexamethasone
1
2014
344
0.030
Why?
Insulin-Like Growth Factor I
1
2013
115
0.030
Why?
Chemoradiotherapy
1
2015
304
0.030
Why?
Triazoles
1
2013
107
0.030
Why?
Induction Chemotherapy
1
2013
153
0.020
Why?
Polymorphism, Single Nucleotide
1
2020
2421
0.020
Why?
Quality of Life
1
2020
1687
0.020
Why?
Extracellular Matrix
1
2013
248
0.020
Why?
Drug Administration Schedule
1
2013
866
0.020
Why?
Neoplasm Grading
1
2013
377
0.020
Why?
Surveys and Questionnaires
1
2019
2667
0.020
Why?
Neuroblastoma
1
2014
391
0.020
Why?
Up-Regulation
1
2013
728
0.020
Why?
DNA-Binding Proteins
2
2006
1247
0.020
Why?
Carcinoma, Hepatocellular
1
2014
402
0.020
Why?
Adolescent
2
2020
9341
0.020
Why?
Senegal
1
2009
4
0.020
Why?
Nigeria
1
2009
157
0.020
Why?
Health Surveys
1
2009
239
0.020
Why?
Apoptosis
1
2015
1723
0.020
Why?
Transcription Factors
2
2006
1673
0.020
Why?
Liver Neoplasms
1
2014
760
0.020
Why?
Genetic Markers
1
2008
477
0.020
Why?
Cyclin A1
1
2006
2
0.020
Why?
Cathepsin K
1
2006
3
0.020
Why?
MSX1 Transcription Factor
1
2006
3
0.020
Why?
Carcinoma, Adenosquamous
1
2006
12
0.020
Why?
Cyclin A
1
2006
29
0.020
Why?
Cathepsins
1
2006
21
0.020
Why?
DNA Modification Methylases
1
2006
28
0.020
Why?
T-Lymphocytes
1
2013
1228
0.020
Why?
DNA Repair
1
2008
363
0.020
Why?
Keratin-5
1
2006
3
0.020
Why?
Keratin-6
1
2006
3
0.020
Why?
Keratins
1
2006
63
0.020
Why?
Neprilysin
1
2006
41
0.020
Why?
Vimentin
1
2006
46
0.020
Why?
Sample Size
1
2006
125
0.020
Why?
Hydroxamic Acids
1
2005
50
0.020
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2007
888
0.020
Why?
Genes, Tumor Suppressor
1
2006
154
0.020
Why?
Cluster Analysis
1
2006
372
0.020
Why?
Gene Dosage
1
2005
210
0.020
Why?
Tumor Cells, Cultured
1
2006
1049
0.010
Why?
Phosphoproteins
1
2006
261
0.010
Why?
Muscle, Smooth
1
2006
355
0.010
Why?
Tumor Suppressor Proteins
1
2006
290
0.010
Why?
Lymphocytes
1
2005
470
0.010
Why?
Trans-Activators
1
2006
443
0.010
Why?
Actins
1
2006
469
0.010
Why?
Research Design
1
2006
590
0.010
Why?
Colonic Neoplasms
1
2006
571
0.010
Why?
Gene Expression
1
2005
1312
0.010
Why?
Carcinoma, Squamous Cell
1
2006
1096
0.010
Why?
Reproducibility of Results
1
2006
2782
0.010
Why?
RNA, Messenger
1
2005
2030
0.010
Why?
Adenocarcinoma
1
2006
1182
0.010
Why?
Phenotype
1
2006
2467
0.010
Why?
Genetic Predisposition to Disease
1
2006
2362
0.010
Why?
Malocclusion, Angle Class I
1
1995
1
0.010
Why?
Malocclusion, Angle Class II
1
1995
1
0.010
Why?
Mesial Movement of Teeth
1
1995
1
0.010
Why?
Incisor
1
1995
7
0.010
Why?
Tooth Extraction
1
1995
11
0.010
Why?
Cephalometry
1
1995
50
0.010
Why?
Molar
1
1995
22
0.010
Why?
Prostatic Neoplasms
1
2006
1751
0.010
Why?
Child
1
1995
7215
0.000
Why?
Nanda's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (321)
Explore
_
Co-Authors (73)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_